Skip to main content
. 2022 Aug 6;64:101566. doi: 10.1016/j.molmet.2022.101566

Figure 3.

Figure 3

Drp1 knockdown mitigates liver steatosis, circulating hyperlipidemia, body weight gain and the increase in circulating ALT, but not of AST, in mice with GAN diet induced NASH. (A) Study design for testing hepatocyte-specific Drp1 knockdown efficacy in the preclinical NASH mouse model of GAN diet feeding for a total of 36 weeks. (B-J) Mice fed regular chow (RC) or GAN diet for 24 weeks before being injected weekly with PBS (control vehicle) or NAG Drp1 siRNA (NAG-Drp1si) for 12 weeks. Data presented are the mean ± SEM. RC/PBS n = 8, GAN/PBS n = 12, GAN/NAG-Drp1si n = 12, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 one-way ANOVA. B) Liver Dnm1l mRNA content analyzed by qPCR. (C) Terminal body weights. (D) Percent of liver fat mass. (E) Plasma cholesterol (TC), (F) triglycerides (TG) and (G) fed glycemia. (H) Circulating ALT and AST levels. (I) Plasma Fgf21 protein content. J) Plasma Gdf15 protein content.